COVID-19 Treatments in Canada

Did you know that there are several treatments for COVID-19?

There are now treatments for COVID-19 that can help prevent hospitalizations and death, especially in those who are at greater risk for severe complications. They are most beneficial taken within 5 to 7 days of the onset of mild or moderate symptoms. Eligibility to receive treatment depends on your risk factors, chronic conditions, age, whether you are vaccinated, and where you reside in Canada.

Since the identification of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its subsequent variants, researchers have been developing vaccines to prevent infection and one prevention medication. Click here for information about vaccines and medication to prevent COVID-19 infection.

Those who have been fully vaccinated against the virus (2 doses) and had booster shots, as appropriate, generally have self-limiting symptoms and recover naturally.

Who is at Risk of Severe COVID-19?

Not everyone needs or is eligible for COVID-19 treatment. All the approved treatments so far have only been studied in, and approved for, people who are at high risk of severe infection, hospitalization, and/or death. There was variability in how the different treatment studies classified high risk individuals and healthcare professionals and health authorities across Canada are still debating the criteria for who should be considered in this group. For example, some studies classified all adults over 50 years of age to be at high risk, while other studies only classified these adults as high risk if they also had a significant chronic health condition.

If you have a health condition that weakens your immune system (immunocompromised), you are likely to be eligible for treatments and, in some jurisdictions, you are considered clinically extremely vulnerable (CEV). This can include any of the following:1

  • solid organ transplant and receiving immunosuppressive treatment
  • bone marrow or stem cell transplant
  • treatment for cancer, including haematological malignancies
  • diagnosis with a moderate to severe primary immunodeficiency
  • untreated or advanced HIV (CD4 ≤ 200 cells/mm3)
  • on dialysis or have severe kidney disease and receiving any immunosuppressants
  • taking immunosuppressive treatment
  • high dose of steroids
  • biologics (for example: adalimumab, etanercept, infliximab, interferon products)
  • anti-CD20 agents (for example: rituximab, ocrelizumab, ofatumumab, obinutuzumab, ibritumomab, tositumomab)
  • B-cell depleting agents (for example: epratuzumab, belimumab, rituximab, atacicept, anti-BR3, alemtuzumab)
  • immune-suppressing agents (for example: cyclophosphamide, cisplatin, methotrexate)
  • cystic fibrosis
  • severe chronic obstructive pulmonary disease (COPD) or asthma requiring hospitalization in the last year
  • severe lung disease with at least one of the following:
  • long-term home oxygen therapy
  • assessment for a lung transplant
  • severe pulmonary arterial hypertension
  • severe pulmonary fibrosis/interstitial lung disease
  • rare blood disorders
  • diabetes treated with insulin
  • splenectomy or functional asplenia
  • significant developmental disabilities, including:
  • down syndrome
  • cerebral palsy
  • intellectual developmental disability (IDD)
  • pregnant and with a serious heart disease (congenital or acquired) that requires observation by a cardiologist throughout pregnancy
  • neurological or other conditions causing significant muscle weakness around lungs requiring the use of a ventilator or bi-level positive airway pressure (Bi-PAP)
  • on dialysis or have stage 5 chronic kidney disease (eGFR ≤ 15ml/min)
  • unvaccinated and are 50 years of age or older, or have one or more chronic conditions
  • have not received the recommended doses of a COVID-19 vaccine and its boosters and are 50 or over with 1 or more chronic conditions (e.g., asthma, chronic respiratory disease, diabetes, heart failure, inflammatory bowel disease, kidney disease, obesity, stroke, and others)
  • 70+ with 3 or more chronic conditions
  • self-identifies as Indigenous and are:
    • 70+
    • 50+ and haven’t had 3 doses of a COVID-19 vaccine

Each province and territory have developed its own criteria for defining high risk individuals who are eligible to receive COVID-19 treatment. This provincial and territorial list will help you identify your risk and regional eligibility for receiving treatment.

COVID-19 Treatments

Currently, Health Canada has approved a few treatments for COVID-19. Medication availability and access varies by province and territory, and we have all the available links listed below. For more immediate information about your specific situation, ask your local pharmacist, doctor, or public health authority to learn more about which treatments are available in your region and how to access them.

Many of these treatments must begin within 5 to 7 days of symptom onset to work as expected. You must act quickly if you test positive for COVID-19 and have symptoms. Individual access to these medications is conditional, factoring in your risk for severe infection and hospitalization, your age, and whether you have any chronic condition(s), as explained above. You vaccination status is also a factor.

The medications listed below do not stop you from contracting COVID-19. They can only prevent severe symptoms and/or hospitalization in those who are high risk.

Nirmatrelvir and Ritonavir (Paxlovid™)3

Paxlovid™ is the only oral medication available in Canada for the treatment of adults (18 years of age and older) who are at high risk of hospitalization or death due to COVID-19. A treatment course is 5 days. Nirmatrelvir, an antiviral agent, works to stop the virus from replicating in your body. It is combined with ritonavir, which boosts the levels of nirmatrelvir in the body. This can help you overcome the infection and reduce risk of hospitalization and death. You can take Paxlovid™ in any healthcare setting or at home. In some cases, e.g., in BC, a healthcare professional might follow up with you about your treatment.

Remdesivir (Veklury®)5

Veklury® is administered by intravenous (IV) infusion in a healthcare setting, once daily for 3 days. It is used for in-hospital patients as well as those who are at high risk of hospitalization or death due to COVID-19. Remdesivir is an antiviral drug that works by stopping the virus from replicating in your body and is currently one of the main IV medications recommended by the various Canadian health authorities.

Alberta: https://www.albertahealthservices.ca/topics/Page17753.aspx

British Columbia: https://www2.gov.bc.ca/gov/content/covid-19/vaccine/treatments

Manitoba: N/A

New Brunswick: N/A

Newfoundland and Labrador: N/A

Northwest Territories: N/A

Nova Scotia: https://www.nshealth.ca/reportandsupport 1 or call 1-833-797-7772

Nunavut: N/A

Ontario: https://covid-19.ontario.ca/covid-19-treatments

Prince Edward Island: There is limited access to treatments, call 811 telehealth service for more information

Quebec: There is limited access to remdesivir. Contact your healthcare provider for more information. https://www.inesss.qc.ca/covid-19/traitements-specifiques-a-la-covid-19/remdesivir.html

Saskatchewan: https://www.saskatchewan.ca/government/health-care-administration-and-provider-resources/treatment-procedures-and-guidelines/emerging-public-health-issues/2019-novel-coronavirus/testing-information/covid-19-treatments#antiviral-medication-remdesivir

Yukon: N/A

Other Treatments

The following treatments have also been approved by Health Canada, but the use and availability of these medications varies by province or territory and, if recommended, the healthcare professionals assessing you for COVID-19 treatment will provide you with information on how to access them.

Evusheld is an injected intramuscular (IM) medication for the treatment of mild to moderate COVID-19 infection in those 12 years of age or older and weighing 40 kg or more. It must be administered within 7 days of COVID-19 symptom onset to help reduce the risk for a severe COVID-19 infection. It is administered as two IM injections at the same time in separate locations of the body. Evusheld™ contains two monoclonal antibodies which block the attachment of the SARS-CoV-2 spike protein to human cells and prevent the replication of the virus, reducing the severity of the infection.

Evusheld™ is also approved in Canada for the prevention of COVID-19, known as pre-exposure prophylaxis of COVID-19, and for use among those who have not had a recent exposure to someone with an active COVID-19 infection,  are immunocompromised, and/or are unable to receive COVID-19 vaccination. Since a marginally higher rate of cardiovascular events were seen in studies comparing this treatment to placebo, those with cardiac risk factors should discuss the risks and benefits with their prescriber before starting therapy. However, recent data and a Health Canada advisory indicates that this treatment may not have significant protection against newer Omicron variants.6 Please check the guidelines of your local health authority (listed below).

Provincial and territorial information about this medication:

On 2022-10-18, Health Canada authorized Evusheld™ for the treatment of COVID-19. We will update the links below as more information becomes available.

Alberta: AHS no longer recommends Evusheld™ due to lack of efficacy against newer variants. However, it is still available on a case-by-case basis. Please consult your doctor.

British Columbia: On November 23, 2022, BC CDC announced that it does not recommend the use of Evusheld™ for the prevention of COVID-19, including its use among severely immunocompromised individuals.7

Manitoba: https://sharedhealthmb.ca/covid19/treatment/

New Brunswick: N/A

Newfoundland and Labrador: N/A

Northwest Territories: N/A

Nova Scotia: N/A

Nunavut: N/A

Ontario:  Effective November 2022, Ontario Health no longer recommends the use of Evusheld™ for the prevention or treatment of COVID-19.8

Prince Edward Island: N/A

Quebec:  On December 16, 2022, INESSS issued a notice to not recommend Evusheld™ for the prevention and treatment of COVID-19.9

Saskatchewan: N/A

Yukon: N/A

Bamlanivimab is a medication administered as a single intravenous (IV) infusion for the treatment of COVID-19 in people 12 years of age and older, who are at high risk of hospitalization or death from the infection. It is a monoclonal antibody that binds specifically to the spike protein of SARS-CoV-2, which stops the virus from replicating in the body.

On February 13, 2023, bamlanivimab was discontinued in Canada.11

This combination medication is administered as a single intravenous (IV) infusion for the treatment of COVID-19 in people 12 years of age and older, who are at high risk of hospitalization or death from the infection. Casirivimab and imdevimab are two human monoclonal antibodies that bind to the spike protein of SARS-CoV-2 and stop it from replicating in the body.

Use and availability of this product varies by province or territory and, if recommended, healthcare professionals assessing you for COVID-19 treatment will provide you with information on how to access it.

This medication is administered as a single intravenous (IV) infusion for the treatment of COVID-19 in people 12 years of age and older, who are at high risk of hospitalization or death due to the infection. Sotrovimab is a monoclonal antibody that binds to the spike protein of SARS-CoV-2 and stops it from replicating in the body.

Use and availability of this product varies by province or territory and, if recommended, healthcare professionals assessing you for COVID-19 treatment will provide you with information on how to access it.

Provincial and territorial information about this medication:

Alberta: AHS no longer recommends Xevudy® due to lack of efficacy against newer variants. However, it is still available on a case-by-casis. Please consult your doctor.

British Columbia: N/A

Manitoba: N/A

New Brunswick: N/A

Newfoundland and Labrador: N/A

Northwest Territories: N/A

Nova Scotia: https://www.nshealth.ca/reportandsupport or call 1-833-797-7772

Nunavut: N/A

Ontario:  N/A

Prince Edward Island: N/A

Quebec: Sotrovimab is available in the province. Contact your healthcare provider for more information.

Saskatchewan: N/A

Yukon: N/A

It’s a Balance

Some medications, such as Paxlovid™, have drug-to-drug interactions, and you might need to stop or reduce the dose of your usual medications during treatment. If your existing medications cannot be adjusted and there is a significant drug interaction, you shouldn’t use Paxlovid™. It’s also important to consider the potential side effects of these treatments. Medications requiring an infusion may sometimes cause reactions, including itchiness, rash, flushing, shortness of breath, nausea, or vomiting. Before starting any type of COVID-19 treatment, you should immediately discuss the benefits and risks with your doctor or pharmacist to ensure that the therapy is safe and effective.

Selecting a COVID-19 Treatment

Selection of a COVID-19 treatment depends on which options are available, the feasibility of administering an injection or intravenous infusion, the potential for drug-to-drug interactions, and the virus variant or sub-variant suspected. For example, studies14 show that Paxlovid™ is effective against the BA.2 sub-variant of the Omicron variant and is the first line treatment in most regions in Canada. Veklury® has demonstrated some success against Alpha, Beta, Gamma, Epsilon, Kappa, Lambda, Iota, and Zeta variants but less activity against Delta and Omicron variants.2 Xevudy® was shown to be effective against earlier variants of COVID-19 but is less effective against the newer Omicron subvariants such as BA.2 and others which are becoming the variants of concern. The treatment selected will continue to change as we identify more variants and subvariants of concern in the population over time.

CAUTION: Unproven Treatments and Poisonings

While the internet can be a wealth of information and education, it also contains a lot of misinformation. Two unproven treatments that became prominent early in the COVID-19 pandemic include ivermectin (Stromectol®), an antiparasitic drug, and hydroxychloroquine sulfate (Plaquenil®), a drug used to prevent and treat malaria in areas where malaria remains sensitive to chloroquine or to treat some autoimmune conditions. Neither one of these treatments has been shown to have any positive impact in the treatment of COVID-19 and they can cause severe side effects when used inappropriately. There have been poisonings related to the misuse of veterinary-grade ivermectin in Canada, causing hospitalizations. Protect yourself from misinformation by discussing treatment options with your healthcare provider and ensure that you are getting your information from reputable and trustworthy sources.


Updated: 2023-01-25
Sources
• BC CDC. https://www.bccdc.ca/health-info/diseases-conditions/covid-19/if-you-have-covid-19
• Public Health Agency of Canada. https://www.canada.ca/en/public-health/services/diseases/coronavirus-disease-covid-19.html.
References
1. Government of British Columbia. High Risk Populations (immunocompromised). August 2022. https://www2.gov.bc.ca/gov/content/covid-19/vaccine/treatments#immunocompromised.
2. Adapted from BC CDC guidelines. May 2022. http://www.bccdc.ca/health-info/diseases-conditions/covid-19/if-you-have-covid-19.
3. Pfizer Canada ULC. Paxlovid. Health Canada. January 2022. https://covid-vaccine.canada.ca/paxlovid/product-details.
4. Government of Prince Edward Island. Health PEI urges patience as cases increase and demand increases for Paxlovid. July 2022. https://www.princeedwardisland.ca/en/news/health-pei-urges-patience-as-cases-increase-and-demand-increases-for-paxlovid.
5. Gilead Sciences Canada Inc. Veklury®. Health Canada. October 2020. https://covid-vaccine.canada.ca/veklury/product-details.
6. Health Canada. EVUSHELD (tixagevimab and cilgavimab for injection) – Risk of Prophylaxis or Treatment Failure due to Antiviral Resistance to specific SARS-CoV-2 Subvariants. January 2023. https://recalls-rappels.canada.ca/en/alert-recall/evusheld-tixagevimab-and-cilgavimab-injection-risk-prophylaxis-or-treatment-failure.
7. BC COVID Therapeutics Committee. Clinical Practice Guide for the Use of Tixagevimab/Cilgavimab (Evusheld™) for Pre-exposure Prophylaxiss against COVID-19. BC Centre for Disease Control. November 2022. http://www.bccdc.ca/Health-Professionals-Site/Documents/COVID-treatment/ClinicalPracticeGuide_Evusheld.pdf.
8. What you need to know about Evusheld: For people who have received Evusheld in the past. Ontario Health. December 2022. https://www.ontariohealth.ca/sites/ontariohealth/files/2022-05/Patient%20Handout%20-%20Evusheld%20-%20EN.pdf.
9. Tixagévimab/Cilgavimab (Evusheld) en prophylaxie préexposition. Institut national d’excellence en santé et en services sociaux. December 2022. Available at: https://www.inesss.qc.ca/en/covid-19/traitements-specifiques-a-la-covid-19/tixagevimab-/-cilgavimab-evusheld-en-prophylaxie-preexposition.html.
10. Eli Lilly Canada Inc. Bamlanivimab for injection. Health Canada. April 2021. https://covid-vaccine.canada.ca/bamlanivimab/product-details.
11. Reports for BAMLANIVIMAB. Drug Shortages Canada. https://www.drugshortagescanada.ca/drug/101231.
12. Hoffman-La Roche Limited. Casirivimab and imdevimab for injection. Health Canada. June 2021. https://covid-vaccine.canada.ca/casirivimab-and-imdevimab/product-details.
13. GlaxoSmithKline Inc. Sotrovimab for injection. Health Canada. September 2021. https://covid-vaccine.canada.ca/sotrovimab/product-details.
14. Pfizer Inc. Media Release. Pfizer Shares In Vitro Efficacy of Novel COVID-19 Oral Treatment Against Omicron Variant. https://www.pfizer.com/news/press-release/press-release-detail/pfizer-shares-vitro-efficacy-novel-covid-19-oral-treatment 2022-01-18.
Photo: © tonefotografia | Bigstockphoto.com
This information is vetted by a number of healthcare experts and updated regularly to remain relevant. However, we cannot guarantee that all external links are current. We thank all of the content contributors who helped develop this page.